By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juvaris BioTherapeutics 

866 Malcolm Road
Suite 100
Burlingame  California  94010  U.S.A.
Phone: 650-259-1800 Fax: 650-697-8828



Company News
Juvaris BioTherapeutics Announces License to Colby Pharmaceutical for JVRS-100 and CLDC (Cationic Lipid-DNA Complex) Platform for Human Health 9/9/2011 10:40:05 AM
Juvaris BioTherapeutics Announces Publication of Preclinical Anti-Leukemic Effects of JVRS-100 Immunotherapy 9/30/2010 9:58:05 AM
Juvaris BioTherapeutics Completes Second Close on $25 Million Series B Financing 1/27/2010 7:10:05 AM
Juvaris BioTherapeutics Initiates Phase 2 Study of Influenza Vaccine Adjuvant in Elderly Population 11/2/2009 9:57:49 AM
Juvaris BioTherapeutics Announces First Close on $25 Million Series B Financing 9/17/2009 7:09:25 AM
Juvaris BioTherapeutics Announces Strategic Collaboration with Antigen Discovery Inc. 6/29/2009 12:06:23 PM
Juvaris BioTherapeutics' Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies 5/8/2009 9:16:28 AM
Juvaris BioTherapeutics' Vaccine Adjuvant, JVRS-100, Generates Superior T-Cell Mediated Immune Responses to Influenza in Clinical Trial 4/27/2009 10:24:09 AM
Juvaris BioTherapeutics Announces Progress in Alliance with Bayer Animal Health 1/9/2009 9:50:18 AM
Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine 1/8/2009 9:31:45 AM